Linda C. Laux, MD

Clinical and Community Trials

Biography

  • Associate Division Head, Neurology
  • Section Head, Epilepsy Center
  • Lorna S. and James P. Langdon Chair in Pediatric Neurology
  • Associate Professor of Pediatrics (Neurology and Epilepsy), Northwestern University Feinberg School of Medicine

See Lurie Children's Provider Profile

Education and Background

  • Fellowship in Pediatric Epilepsy, Children's Memorial Hospital 2001
  • Fellowship in Neurology/Child Neurology, Barrow's Neurologic Institute/St. Joseph's Hospital 1994-1997
  • Residency in Pediatrics, University of Arizona Health Science Center 1990-1993
  • St. Louis University 1990

Clinical Studies

Recruiting

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Recruiting

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies

Recruiting

Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Subjects With SCN8A-DEE

Recruiting

EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome

Recruiting

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

Recruiting

An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

Recruiting

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Recruiting

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

Recruiting

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Publications

Dec. 22, 2023

Severe communication delays are independent of seizure burden and persist despite contemporary treatments in SCN1A+ Dravet syndrome: Insights from the ENVISION natural history study.

Aug. 17, 2023

Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial.

Jul. 01, 2022

COVID-19 vaccine in patients with Dravet syndrome: Observations and real-world experiences.

See all publications

Similar Researchers

Clinical and Community Trials

Sandi K. Lam, MD, MBA

Research Interests

Health Services Research Using Hospital and National Data to Look at Patterns of Care and Health Outcomes to Understand Disparities, Healthcare Utilization, Access to Care, Comparative Effectiveness of Medical and Surgical Treatments of Pediatric Neurologic Conditions

Recent Publication

A Well-Being Well-Check for Neurosurgery: Evidence-Based Suggestions for Our Specialty Based on a Systematic Review.

Feb. 24, 2024

Joshua L. Goldstein, MD

Research Interests

Neurocritical Care, Epilepsy, Seizures

Recent Publication

Pediatric status epilepticus management by Emergency Medical Services (the pSERG cohort).

Jul. 16, 2023
Clinical and Community Trials

Joshua B. Ewen, MD

Research Interests

Cognition in Developmental Disabilities (Autism, ADHD), Epilepsy, Brain-Behavior Relationships, Theory-Based Psychology, Motor Control, Biomarker Validation

Rajit K. Basu, MD, MS

Research Interests

Critical care nephrology, Extracorporeal support, Blood purification, Critical care education, Industry partnerships, Chronic critical illness, Pediatric and community partnership, Career development, Leadership

Recent Publication

External validation of the modified sepsis renal angina index for prediction of severe acute kidney injury in children with septic shock.

Nov. 28, 2023

Rukhmi V. Bhat, MD

Recent Publication

Intravenous fluid therapy and hospital outcomes for vaso-occlusive episodes in children, adolescents, and young adults with sickle cell disease.

Nov. 27, 2023
Clinical and Community Trials

Joyce Wu, MD

Recent Publication

Common epilepsy variants from the general population are not associated with epilepsy among individuals with tuberous sclerosis complex.

Feb. 17, 2024